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DObjective: This analysis was undertaken to evaluate the results of persistent atrial fibrillation ablation procedures
concomitant to open surgery and to identify risk factors for persistent atrial fibrillation recurrence.
Methods: Since 2001, a total of 325 consecutive patients with persistent atrial fibrillation (duration, 0.5–33 years)
have undergone persistent atrial fibrillation ablation concomitant to open surgery by creating 2 encircling isola-
tion lesions around the left and right pulmonary veins and a connecting lesion between both with the use of radio-
frequency ablation procedures. Patients were restudied at discharge, 3 months, and 3 years after surgery.
Results: Survivals at the time of reexamination at discharge, 3 months, and 3 years were 97.8%, 96.2%, and
94.4%, respectively. Stable sinus rhythm could be documented in 72.1%, 73.9%, and 75.6% of surviving pa-
tients, respectively. Long-term persistent atrial fibrillation before surgery and a larger left atrium were predictive
of postoperative persistent atrial fibrillation return (P<.001). Statistical analysis demonstrated cutoff points of 5
years for persistent atrial fibrillation and 55 mm for left atrium diameter; 89.7% of patients with persistent atrial
fibrillation duration of less than 5 years and 84.5% of patients with left atrium size of 55 mm or less were in stable
sinus rhythm at late follow-up. Cardiac rhythm at discharge and at 3 months was predictive of long-term rhythm
prognosis (P<.001). Age, gender, concomitant diseases (eg, arterial hypertension, diabetes, renal insufficiency,
or pulmonary disease), and the underlying cause of heart disease did not significantly influence the postoperative
cardiac rhythm.
Conclusions: The duration of persistent atrial fibrillation and the size of the left atrium are the most reliable
preoperative variables to predict the success rate of ablation concomitant to open surgery. The probability of re-
establishing stable sinus rhythm is excellent when persistent atrial fibrillation duration is short and left atrium size
is small. (J Thorac Cardiovasc Surg 2011;141:377-82)Atrial fibrillation (AF) is the most prevalent cardiac arrhyth-
mia treated in clinical practice. In cardiac surgery, persistent
atrial fibrillation (pAF) is exceptionally important because it
is frequently found as a concomitant disease in patients who
are scheduled for open surgery for other reasons.1 The mor-
bidity associated with pAF results in significantly poorer sur-
vival than in patients with stable sinus rhythm (SR).2 Since
the Cox maze procedure demonstrated that AF can be eradi-
cated, less-invasive ablation procedures were brought to clin-
ical practice a decade ago.3-5 The present study evaluates the
early and late results of a strategy that was started in 2001
using radiofrequency (RF) ablation in patients with
concomitant pAF who were scheduled for open surgery
and identifies the risk factors for postoperative pAF
recurrence. The data of 8 years of clinical experience with
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The investigation comprised 325 consecutive patients with a given indi-
cation for open surgery and concomitant persistent, not paroxysmal, AF (fol-
lowing the terminology of the current American College of Cardiology/
American Heart Association/European Society of Cardiology guidelines6).
This analysis included only patients who had persistent, not paroxysmal,
AF for at least 0.5 years (median: 4.0 years, Perc25/75 1.5/8.0; range:
0.5–33 years) and were scheduled for surgery at the Asklepios Klinik St
Georg between February 2001 and January 2009. The patient characteristics
are shown in Table 1. Exclusion criteria for concomitant ablation in other
cases with pAF (n ¼ 60), as defined in 2001, were pAF duration of less
than 0.5 years, emergency operation, severely reduced left ventricular ejec-
tion fraction (<15%), acute endocarditis or myocardial infarction (<7 days),
considerable cachexia (body mass index  18), and severe intracardiac
thrombosis or extreme left atrium (LA) size (diameter  72 mm).Surgical Technique
The ablation procedure included a bilateral isolation of the right pulmo-
nary veins (RPVs) and left pulmonary veins (LPVs), which were connected
in the middle by a transverse lesion across the posterior LA wall. When the
LA had to be opened (eg, during mitral valve [MV] surgery), the Cobra de-
vice (Boston Scientific Corp, San Jose, Calif) was used for RF ablation
(100 W RF power for 120 seconds); the local temperature was set at
70C (monopolar endocardial application). For this procedure, the LA
was opened via a standard left atriotomy and MV analysis was performed.
Next, by performing a left atriotomy, the first ablation lesion completed the
isolation of the RPVs from the inferior to the superior RPV (Figure 1). Iso-
lation of the LPVs was performed with a semicircular ablation line close to
the inferior LPV and another one around the superior LPV. These wererdiovascular Surgery c Volume 141, Number 2 377
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
DC ¼ direct current
ECG ¼ electrocardiogram
LA ¼ left atrium
LPV ¼ left pulmonary vein
MV ¼ mitral valve
NYHA ¼ New York Heart Association
OR ¼ odds ratio
pAF ¼ persistent atrial fibrillation
RF ¼ radiofrequency
RPV ¼ right pulmonary vein
SR ¼ sinus rhythm
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Dconnected by a transverse lesion. Arrangements to avoid thermic esophageal
injury were as follows: The ablation was performed under direct view dur-
ing conventional open surgery only, the transesophageal echocardiogram
probe was removed during the ablation procedure, a dry compress was
passed behind the LA before energy delivery, the flexible ablation probe
was adapted to the tissue without pressure, the local temperature was set
at only 70C, and cachectic patients were excluded.
In cases without a left atriotomy (eg, aortic valve procedures or coronary
artery bypass grafting [CABG]), the Atricure device (Atricure Inc, Cincin-
nati, Ohio) was used for bipolar RF ablation: Isolation of the RPVs and
LPVs was performed on cardiopulmonary bypass with the heart beating
by impacting the atrial tissue between the jaws of the Atricure hand piece
and delivering energy with a local temperature of 40C to 55C. Ablation
was terminated when the ablation and sensing unit indicated that the tissue
conductance was at least 10 seconds less than 2.5 millisiemens, which is in
parallel with transmurality of the lesion. Next, a purse-string 2-0 Ethibond
suture (Ethicon, Johnson & Johnson Inc, New Brunswick, NJ) was set at the
posterior LA wall. The distal jaw was inserted through an incision in the
direction of the LPVs, and ablation was performed after clamp closure.
The distal jaw was inserted in the direction of the RPVs, and the connecting
lesion was completed (Figure 1). The purse-string suture was closed and
protected with a 3-0 Prolene (Ethicon) suture. The LA appendage was oc-
cluded routinely from the endocardial side (MV cases; using two 3-0 Prolene
running sutures) or the epicardial side (non-MV cases; using 4-0 Prolene
[Ethicon] sutures; double layer) in cases with an LA diameter of more
than 55 mm.
Management of Cardiac Rhythm and Follow-up
Transthoracic echocardiogram and standard 12-lead electrocardiogram
(ECG) were performed on admission and before discharge by an experi-
enced cardiologist. LA size was assessed by evaluating the LA diameter
(anteroposterior diameter on parasternal axis view at end systole). An LA
of more than 55 mm was termed as large (55 mm, small). A tricuspid re-
gurgitation of grade 2 or more documented by transthoracic echocardiogram
was interpreted as an indication to perform concomitant tricuspid valve re-
pair. Amiodarone administration was started with an intravenous bolus of
300 mg before the end of cardiopulmonary bypass, followed by an infusion
of 900 mg/d for 3 days. Oral administration of 5 3 200 mg up to 7 to 10 g
depending on body weight was begun, followed by 1 3 200 mg/d for
3 months. In cases of thyroid disease, amiodarone incompatibility, or other
contraindication for amiodarone administration, sotalol was given alterna-
tively (an intravenous bolus of 10 mg and then 1 mg/kg for 24 hours; oral
administration of 2–3 3 40–80 mg for 3 months). When postoperative378 The Journal of Thoracic and Cardiovascular Surgbradycardia persisted for more than 10 days, the amiodarone/sotalol therapy
was stopped. An indication for permanent pacemaker implantation was bra-
dycardia persisting for 14 days. In cases with early AF recurrence during
hospital stay after saturation with amiodarone/sotalol and after exclusion
of intracardiac thrombosis by transesophageal echocardiogram, direct cur-
rent (DC) cardioversion was recommended. During initial antiarrhythmic
drug saturation, patients were observed for at least 7 days with continuous
monitoring (first in the intensive care unit and then in an intermediate care
unit). Heparin was given after resolution of postoperative bleeding. Patients
with heart valve repair or bioprosthesis received coumarin for 3 months. Pa-
tients with mechanical valves, lifelong anticoagulation, or CABG received
aspirin for lifetime. All survivors were restudied before discharge (n¼ 318;
10  2 days); 307 patients were studied early (3  1 months) and 287 pa-
tients were studied late (3.0  1.6 years) after surgery by standard 12-lead
ECG and clinical examination. A standard 24-hour ECG registry also was
performed at early and late follow-ups. According to the protocol during
the hospital stay, the following variables and events were documented:
age, gender, pAF duration, LA size, left ventricular ejection fraction, cause
of heart disease, concomitant pulmonary disease, diabetes, arterial hyperten-
sion, renal insufficiency, New York Heart Association (NYHA) class, aortic
crossclamping time, cardiopulmonary bypass time, total operation time, ab-
lation time, total ablation procedure time, postoperative drug therapy, per-
manent pacemaker implantation, early AF recurrence, DC cardioversion
(successful, unsuccessful), cardiac and noncardiac death, reoperation for
bleeding, perioperative myocardial infarction, cerebrovascular events,
pneumonia, and wound infection. At follow-up, the following variables
and events were noted: cardiac and noncardiac death, cardiac rhythm, reop-
eration for recurrent heart disease, endocarditis, myocardial infarction,
stroke, anticoagulation, and NYHA class.
Statistical Analysis
Quantitative preoperative and operative data were described by arithme-
tic mean standard deviation or (if appropriate) by median and Perc25/75.
Qualitative distributed data were presented as absolute frequencies. For data
assessment, an explorative data analysis was performed; no adjustments for
multiple tests were calculated. Univariate and multivariate binary logistic
regression models were used to evaluate pAF recurrence and persistence
early and late after surgery. Continuous measurements and parameters
grouped by clinical relevant values (eg, LA size  55 mm vs< 55 mm;
pAF duration  5 years vs<5 years) were included. Qualitative character-
istics were also compared using chi-square tests (Fisher’s exact test and
McNemar test). Changes in NYHA class were investigated using the Fried-
man test (Monte Carlo method; upper bound of 99% confidence given). All
P values were 2 tailed and interpreted as nominal. Analysis was performed
with the Statistical Package for the Social Sciences for Windows 11.5.2.1
(SPSS Inc, Chicago, Ill), which uses the label ‘‘Exp(B)’’ for the odds ratio
(OR), showing the OR of the independent with the dependent variable and
the predicted change in odds for a unit increase in the corresponding inde-
pendent variable (ORs<1 correspond to decreases; ORs>1.0 correspond
to increases in odds; ORs  1.0 indicate that unit changes in that indepen-
dent variable do not affect the dependent variable).
RESULTS
Of 325 cases in 201 patients, ablation was performed con-
comitant to MV surgery (61.8%). In 124 patients, other pro-
cedures (eg, aortic valve replacement or CABG; 38.2%)
were carried out. All relevant surgery data are shown in
Table 2. Hospital mortality was 2.2% (3 noncardiac and 4
cardiac deaths; 3/7 patients died in SR, 4/7 patients had
AF). One patient (0.3%) underwent reoperation for bleed-
ing, 2 patients (0.6%) had perioperative myocardial infarc-
tion, 17 patients (5.2%) had cerebrovascular eventsery c February 2011
FIGURE 1. Lesion pattern of ablation, which was normally performed in 1
to 4 steps: isolation of RPVs and LPVs plus a connecting lesion on the pos-
terior LA wall using monopolar endocardial RF ablation during MV surgery
(top) or bipolar RF ablation in non-MV cases (bottom). The LA appendage
was sutured routinely from the endocardial side (MV cases) or epicardially
(non-MV cases) in patients with an LA diameter more than 55 mm. LAA,
Left atrial appendage; LPV, left pulmonary vein; RPV, right pulmonary
vein; MV, mitral valve; RF, radiofrequency.
TABLE 1. Characteristics of 325 patients with concomitant persistent
atrial fibrillation
Age, y 70  9 (36–92)
Gender, male/female 196/129 (60.3%/39.7%)
euroSCORE 7.0  2.3 (2–12)
NYHA class 3.1  0.4 (2–4)
LVEF,% 53  13 (15–88)
pAF duration, y 5.8  6.0 (0.5–33; median:
4.0 1.5/8; IQR: 6.0)
LA diameter,* mm 53  7 (36–71)
Severe MV disease 201 (61.8%)
Significant CAD 116 (35.7%)
Relevant TR (grade  2) 91 (28.0%)
Severe AV disease 66 (20.3%)
Anticoagulation (coumarin) 214 (65.8%)
History of failed interventional
AF ablation
16 (4.9%)
Failed DC cardioversionþantiarrhythmic
med.
110 (33.8%)
AF, Atrial fibrillation; AV, aortic valve; CAD, coronary artery disease; LA, left atrium;
LVEF, left ventricular ejection fraction; MV, mitral valve; NYHA, New York Heart As-
sociation; pAF, persistent atrial fibrillation; TV, tricuspid valve; IQR, interquartile
range. The euroSCORE is an established score to evaluate the predicted risk of cardiac
operations (low risk: 1–2 points; moderate risk: 3–5 points; high risk:  6 points).
*The LA diameter at discharge (10 2 days after surgery) was 49 6 mm. MV cases
(endocardial ablation) had significantly larger LA diameters (56.5  6.2 mm) but
shorter duration of pAF (5.6 6.0 years; median, 4.0) than non-MV cases (bipolar ab-
lation, LA diameter: 48.6 4.7 mm; pAF duration: 6.0 6.1 years; median, 4.0 years;
P<.001 and P ¼ .095, respectively). Patients with isolated CABG had an LA size of
47.9  4.4 mm and a pAF duration of 6.9  7.0 years (median, 5.0 years). AV cases
and an LA size of 48.8  4.5 mm and a pAF duration of 50.3  44 years (median,
3 years).
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[1.9%] with stroke, including 2 cases of cerebral hemor-
rhage; the others had ischemia), 10 patients (3.1%) had
pneumonia, and 7 patients (2.2%) had wound infection. A
total of 285 patients (87.7%) received amiodarone, and 40
patients (12.3%) received sotalol. During the hospital stay,
99 of 153 patients (64.7%) with early AF recurrence
(47.1% of all) had DC cardioversion (n ¼ 50 were success-
ful, 50.5%), and 10 patients converted to SR spontaneously.
Fifteen patients had a pacemaker implanted because of per-
sisting bradycardia (4.6%). A short episode of postoperative
self-terminating atrial flutter was observed in 1 patient. Ten
days postoperatively, 229 of 318 patients (72.1%) were dis-
charged in regular SR.
Survival was 96.2% at 3 months and 94.4% at 3 years
follow-up (8 cardiac and 9 noncardiac deaths). The mean
survival time was 80 months (75/83 months; 95% confi-
dence interval). Three patients underwent reoperation for re-
current heart disease, 3 patients had endocarditis, 2 patients
had myocardial infarction, and 4 patients with AF recurrence
had stroke (n ¼ 2 with ischemia after thromboembolism,
n ¼ 2 with hemorrhage). At 3 months, the conversion rate
to stable SR with freedom of AF or atrial flutter was
73.9%. At 3 years, 75.6% of patients had stable SR (be-
tween early and late follow-up, 2 survivors had AF recur-The Journal of Thoracic and Carence and persistence and 6 patients spontaneously
converted to stable SR). At 3 years, 73.4% of mitral cases
(monopolar approach) were in SR and 78.8% of non-
mitral cases (bipolar approach) were in SR (isolated
CABG: 78.3%; isolated aortic valve: 81.8%). At 5 years,
49 of 69 survivors (71.0%) were in SR.
With univariate logistic regression analysis, the variables
preoperative pAF duration and preoperative LA size were
predictive of cardiac rhythm late after surgery (P< .001rdiovascular Surgery c Volume 141, Number 2 379
TABLE 2. Surgical data of 325 patients with concomitant persistent
atrial fibrillation ablation
Procedures: AV surgery (isolated) 44
AV surgery (combined with other surgery) 16
CABG (isolated) 59
CABG (combined with other surgery) 5
MV surgery 78
MV surgery (combined with other surgery) 123
Operation time, min 188  25
CPB time, min 119  27
Aortic crossclamping time, min 78  30
Intermittent crossclamping (CABGþablation) 60
Cardioplegia (Bretschneider solution) 265
Ablation time, min 6.0  2.1
Total ablation procedure time, min 11.8  2.5
ASD, Atrial septal defect; AV, aortic valve; CABG, coronary artery bypass grafting;
CPB, cardiopulmonary bypass; CABG, coronary artery bypass grafting; MV, mitral
valve. Repair was performed in 75.1% of MV cases, and replacement was performed
in 24.9% of MV cases.
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time of surgery was detected as an incremental risk factor
for AF return after ablation (P ¼ .001, at the time of dis-
charge for grouped parameters and continuous measure-
ment; P < .0001 at 3 months and 3 years follow-up).
Larger LA size was found as another risk factor (for grouped
parameters and continuous measurement at 3 months and 3
years follow-up; P ¼ .0002 and P ¼ .0003, respectively).
Statistical data analysis demonstrated cutoff points of 5
years for pAF duration and 55 mm for LA diameter;TABLE 3. Risk factor analysis for persistent atrial fibrillation recurrence
Risk factor 10 d (n ¼ 318)
P value and Exp(B)
pAF duration, mo .001 and 1.072
pAF duration  5 yy .001 and 2.333
LA size, mm .561 and 1.011
LA size>55 mmy .318 and 1.308
Age, y .164 and 1.022
Age  70 y .236 and 1.365
Gender (male) .405 and 0.805
NYHA class, grade .289 and 0.709
LVEF,% .074 and 1.018
Relevant MV disease .229 and 0.731
Relevant AV disease .436 and 0.778
TV disease  grade 2.712 and 0.896
Significant CAD .057 and 1.648
Bipolar ablation .097 and 1.443
Pulmonary disease .308 and 1.383
Arterial hypertension .880 and 1.040
Diabetes mellitus .454 and 0.781
Renal insufficiency .751 and 0.887
AV, Aortic valve; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; MV
missing. yCutoff points in the receiver operating characteristic analysis: Cardiac rhythm at 3
the SPSS’s label for the OR, showing the OR of the independent with the dependent variable
variable (ORs<1 correspond to decreases; ORs>1.0 correspond to increases in odds; ORs
variable).
380 The Journal of Thoracic and Cardiovascular Surg89.7% of patients (148/165) with pAF duration of less
than 5 years and 84.5% of patients (164/194) with LA
size of 55 mm or less were in stable SR at late follow-up.
Moreover, cardiac rhythm at 3 months follow-up was pre-
dictive of long-term rhythm prognosis (P<.001). With mul-
tivariate binary logistic regression analysis, the best
prediction of long-term rhythm prognosis could be shown
for the variable cardiac rhythm at 3 months after surgery
(P< .0001). Gender, preoperative left ventricular ejection
fraction, associated coronary artery or tricuspid valve dis-
ease, the underlying cause of MV disease, concomitant dis-
eases (eg, arterial hypertension, diabetes, renal insufficiency,
or pulmonary disease), and age did not significantly influ-
ence the postoperative cardiac rhythm (Table 3). At late
follow-up, 200 of 287 patients (69.7%) did not require
anticoagulation (all 69 patients with AF and 17 patients
with postoperative SR still received anticoagulation). At 3
months, all patients were taking antiarrhythmic drugs. At
3 years, only 62 patients (21.6%) were not taking any anti-
arrhythmic drugs, and 225 patients (78.4%) were still taking
medication, normally a ß-blocker.
Functional class improved significantly after surgery (de-
crease from NYHA 3.1  0.4 to 1.7  0.5; P< .0001), par-
ticularly when stable SR was achieved (1.5  0.6 [SR] vs
2.1  0.6 [pAF]), with 52% of patients (114/218) in
NYHA I and 41% of patients (90/218) in NYHA II in the
SR group, and only 12% of patients (8/69) in NYHA I
and 68% of patients (47/69) in NYHA II in the group
with AF recurrence (P ¼ .038).after ablation surgery (3 follow-up times)
3 mo (n ¼ 307) 3 y (n ¼ 287*)
P value and Exp(B) P value and Exp(B)
.000003 and 1.114 .000002 and 1.124
.000001 and 4.357 .0000001 and 7.251
.0002 and 1.080 .0003 and 1.100
.0003 and 2.846 .0002 and 3.730
.431 and 1.013 .277 and 1.019
.251 and 1.385 .235 and 1.425
.537 and 0.841 .056 and 0.568
.984 and 1.007 .574 and 1.226
.225 and 1.013 .164 and 1.016
.894 and 0.963 .326 and 1.344
.541 and 0.808 .416 and 0.737
.782 and 1.090 .443 and 1.291
.866 and 1.049 .351 and 0.752
.967 and 1.019 .198 and 1.154
.282 and 1.436 .462 and 1.310
.547 and 1.184 .350 and 1.322
.903 and 1.043 .943 and 1.027
.633 and 0.817 .542 and 1.297
, mitral valve; NYHA, New York Heart Association; TV, tricuspid valve. *n ¼ 22 still
months was predictive of rhythm at late follow-up (P<.0001). The Exp(B) column is
and the predicted change in odds for a unit increase in the corresponding independent
1.0 indicate that unit changes in that independent variable do not affect the dependent
ery c February 2011
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Other research has demonstrated that AF initiation origi-
nates from foci predominantly located in the LA pulmonary
vein junctional area and that AF is maintained by activation
wave fronts of reentrant circuits.7-10 Therefore, surgeons
initially tried to follow the principles of the maze
procedure for AF ablation surgery (combination of PV
isolation and ‘‘complex’’ atrial lesions/incisions to block
reentrant circuits),3-5 even if this concept was invasive and
complicated. Because it was anticipated that the
mechanisms of AF initiation and maintenance vary and are
related with individual electrophysiologic/structural
changes (particularly when AF has become persistent or
permanent),6,11-13 the configuration of the lesion pattern
became a relevant topic. When we began performing AF
ablation surgery in 2001, we tried to simplify the ablation
concept of complex left and right atrial lesions, as reported
by others in 2000,4,5 with the intention of reducing the
number of lesions to what we thought was an absolutely
necessary minimum (PV isolation and an additional
connecting lesion). Nevertheless, postoperative atrial
flutter (what is expected to occur in some cases when, eg,
a mitral isthmus lesion is omitted) was found in only 1 of
325 patients (which is an argument against the necessity of
this lesion and the reason why we did not use more lesions
later). Instead, our data are in line with the experience of
other groups that investigated AF ablation concepts during
open surgery: A block of AF wavelets sustained by foci
predominantly located inside the pulmonary veins and
additional rhythm protection, including medical therapy,
results in SR during a period of approximately 6 months
after surgery in the majority of patients.14-16 However,
reliable long-term data of pAF ablation surgery are scarce
in the literature, and the long-term effects on cardiac rhythm
and survival are still unknown.
RF energy has become the most widely used energy
source for AF ablation surgery. Khargi and colleagues17 de-
scribed an SR conversion rate of 79% at 12 months in 63
non-MV cases and concomitant monopolar endocardial
RF ablation. Other research has demonstrated direct surgical
advantages of bipolar RF ablation compared with a monopo-
lar endocardial approach in non-MV cases because of signif-
icantly shorter ablation times (because the atrial tissue can be
impacted during ablation) and total ablation procedure times
(because standard left atriotomy does not have to be per-
formed).18 Further, a possible deficiency of monopolar
endocardial surgery is that transmurality cannot be ‘‘guaran-
teed,’’ and rare but fatal complications can occur as the result
of deep lesions.19 However, with some simple arrangements
to avoid thermic esophageal injury, the risk for this fatal
complication is low and did not occur in our series of
more than 200 MV cases. The advantage of an endocardial
monopolar application during MV surgery is that the LAThe Journal of Thoracic and Cais already open, and the lesions can be set under direct
view on the atrial tissues. Nevertheless, the surgical advan-
tages of the bipolar RF approach in non-MV cases con-
vinced us to apply the bipolar concept to our standard
procedure to treat permanent AF during CABG or aortic
valve surgery.18 The concepts of monopolar endocardial
and bipolar RF ablation surgery are both useful and reliable
and should be performed according to the surgeon’s practice
and experience.
Our data demonstrate that among patients undergoing
open surgery with pAF, apart from the LA size, the preoper-
ative AF duration particularly influences the ability of estab-
lishing stable SR. These findings confirm the 2006 data of
Melo and colleagues20 from an international registry, who
stated that the LA size is ‘‘the best predictor of (ablation) suc-
cess’’ in a heterogeneous group of patients with MV disease
and different forms of AF, and our earlier research data pub-
lished in 2005.21 In 2008, Beukema and colleagues22 re-
ported a conversion rate to stable SR at 5 years follow-up
in 55% of 285 patients with AF ablation and predominately
MV disease. The predictors of AF recurrence in that study
were also the duration of AF and LA size. In 2005, Gaynor
and colleagues23 reported that the most significant predictor
of late AF recurrence after Cox maze surgery was the dura-
tion of preoperative AF. However, it must be anticipated
that the variable predictor for AF surgery failure as an inde-
pendent risk factor is probably not the LA size or AF duration
itself, but the cellular morphologic/electrophysiologic
changes (‘‘damage’’ ¼ atrial remodeling) correlated with
progressive LA enlargement or long-time AF duration. Our
thesis is that these factors are of significant relevance for
the success of AF ablation surgery. Normally, the decision
to perform concomitant pAF ablation during open surgery
depends mainly on a risk/benefit assessment of the procedure
and the ambition of the individual patient. Our data may help
to assess whether concomitant ablation surgery can be per-
formed with success in an individual patient. The described
inclusion/exclusion criteria for ablation are still followed at
Asklepios Klinik St Georg. However, if a patient has
a high risk for ablation surgery failure, we are now more ret-
icent and sometimes refrain from ablation, particularly when
the clinical situation is complex. In patients with good pre-
conditions (small LA size, short pAF duration, predicted suc-
cess rate [stable SR] of  90%), concomitant ablation
surgery is recommended. We interpret the good long-term
results in our non-MV cases (CABG: 78.3% SR, aortic valve
surgery: 81.8% SR) as a consequence of the small LA size
and the relatively short period of AF, particularly in aortic
valve cases. However, in patients with presumptively ad-
vanced electrical/structural changes, it would be of interest
to identify highly damaged/diseased atrial myocardium out-
side the pulmonary vein and LA junctional area perhaps on
the basis of histologic analysis and fibrillation electrograms,rdiovascular Surgery c Volume 141, Number 2 381
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structures potentially responsible for arrhythmia.Study Limitations
The study was not designed for patients with paroxysmal
AF or pAF persisting for less than 0.5 years (which was our
cutoff set in 2001), and there was no follow-up at exactly
6 months. This limits the comparability with other studies us-
ing other inclusion/exclusion criteria and different follow-up
times. Our data represent only a single-center experience. The
study consists of a heterogeneous group of patients regarding
the type of cardiac pathology, which may have influenced the
results. The data were not evaluated under randomized condi-
tions. Two different ablation devices were used. The trans-
murality of the ablation lesions was not investigated in the
individual patient. For rhythm evaluation at early and late
follow-ups, only 12-lead-ECG, clinical examination, and
standard 24-hour ECG registries were used, but no 7-day Hol-
ter monitoring or implantable ECG loop recorders were used,
which have been shown to improve the completeness of
follow-up data in other studies.24,25 The late follow-up did
not include an echocardiographic investigation of LA func-
tion, which also limits the completeness of the data. Postop-
erative anticoagulation management was not dependent on
the size and contractility of the atria.CONCLUSIONS
The data allow the evaluation of the results of an RF ab-
lation strategy concomitant to open surgery in patients
with pAF duration of 0.5 to 33 years. Regular SR can be
achieved in the majority of patients, and this remains stable
over time. The SR conversion rate is approximately 90% in
cases with ‘‘good preconditions’’ (ie, small LA size and
short pAF duration). Preoperative LA size and pAF duration
were identified as useful variables in predicting the success
rate of ablation surgery. Preoperative long-term pAF and
larger LA size are risk factors for pAF ablation surgery fail-
ure in patients undergoing open surgery. The status of car-
diac rhythm 3 months after surgery is predictive of long-
term rhythm prognosis.References
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